Literature DB >> 2143178

Hypoxic fractions of human tumors xenografted into mice: a review.

S Rockwell1, J E Moulder.   

Abstract

Transplanted tumors in rats and mice have been used extensively in radiobiology studies examining the biological basis and therapeutic implications of hypoxia in solid tumors, and in studies evaluating new agents and regimens which may circumvent the radioprotective effects of hypoxic cells. This use of rodent tumors assumes that data obtained using rapidly-growing transplanted tumors arising in inbred rodents can be extrapolated meaningfully to the treatment of primary and/or metastatic lesions in heterozygous humans. The studies reported here examine one facet of this critical assumption by comparing the hypoxic fractions of transplanted rodent tumors with those of human tumor cell lines xenografted into immune deficient mice. No significant differences were found between the hypoxic fractions of the xenografts and those of mouse tumors. This finding eliminates several possible bases for predicting that the oxygenation of human tumors might be systematically different from that of the rodent tumors often used in preclinical radiobiology studies, and supports the hypothesis that human tumors contain hypoxic cells which may be critical in determining their response to therapy.

Entities:  

Mesh:

Year:  1990        PMID: 2143178     DOI: 10.1016/0360-3016(90)90154-c

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

1.  The hypoxic tumor microenvironment in vivo selects tumor cells with increased survival against genotoxic stresses.

Authors:  Hoon Kim; Qun Lin; Zhong Yun
Journal:  Cancer Lett       Date:  2018-05-30       Impact factor: 8.679

Review 2.  Clinical EPR: unique opportunities and some challenges.

Authors:  Harold M Swartz; Benjamin B Williams; Bassem I Zaki; Alan C Hartford; Lesley A Jarvis; Eunice Y Chen; Richard J Comi; Marc S Ernstoff; Huagang Hou; Nadeem Khan; Steven G Swarts; Ann B Flood; Periannan Kuppusamy
Journal:  Acad Radiol       Date:  2014-02       Impact factor: 3.173

3.  Interlocking triads of growth control in tumors.

Authors:  S Michelson; J T Leith
Journal:  Bull Math Biol       Date:  1995-03       Impact factor: 1.758

4.  Hypoxia and radiation therapy: past history, ongoing research, and future promise.

Authors:  Sara Rockwell; Iwona T Dobrucki; Eugene Y Kim; S Tucker Marrison; Van Thuc Vu
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

5.  Developing oxygen-enhanced magnetic resonance imaging as a prognostic biomarker of radiation response.

Authors:  Derek A White; Zhang Zhang; Li Li; Jeni Gerberich; Strahinja Stojadinovic; Peter Peschke; Ralph P Mason
Journal:  Cancer Lett       Date:  2016-06-03       Impact factor: 8.679

6.  Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy.

Authors:  Rob A Cairns; Ioanna Papandreou; Patrick D Sutphin; Nicholas C Denko
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

Review 7.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

8.  Pimonidazole binding in C6 rat brain glioma: relation with lipid droplet detection.

Authors:  S Zoula; P F J W Rijken; J P W Peters; R Farion; B P J Van der Sanden; A J Van der Kogel; M Décorps; C Rémy
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

9.  Relationship between the melanin content of a human melanoma cell line and its radiosensitivity and uptake of pimonidazole.

Authors:  R el Gamoussi; M D Threadgill; M Prade; I J Stratford; M Guichard
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor or suramin.

Authors:  J T Leith; G Papa; L Quaranto; S Michelson
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.